Oxford Ledge
Search
No licensed closing price on file for CTNM. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.
Contineum Therapeutics, Inc. Class A Common Stock (NASDAQ: CTNM) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 09:48 UTC.
Pipe Therapeutics is a clinical-stage biopharmaceutical company developing small molecule drugs for neuroinflammatory and neurological indications with unmet medical needs. The company's lead asset, PIPE-791, is a brain-penetrant inhibitor of the LPA1 receptor being developed for idiopathic pulmonary fibrosis and chronic pain, with a Phase 2 trial for IPF initiated and Phase 1b data supporting its potential as a differentiated therapy.
Summarized from Contineum Therapeutics, Inc. Class A Common Stock’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗
| Valuation | |
| Return on equity | -33.44% |
Pipe Therapeutics is a clinical-stage biopharmaceutical company developing small molecule drugs for neuroinflammatory and neurological indications with unmet medical needs.
Contineum Therapeutics, Inc. Class A Common Stock's most recent SEC filing on record is a 8-K filed 2026-07-13. All filings link to their SEC EDGAR originals above.
SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 09:48 UTC. This page is also available as JSON at /api/data?ticker=CTNM and is emitted with FAQPage structured data for machine reading.
Charts, 10-year financials, peer comparison, screening and portfolio tracking for CTNM and 5,000+ tickers.
Create a free account — keep CTNMGET /api/data?ticker=CTNM
This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt